![Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors](/docs/US/2024-07-09/US12030885B2/abs.jpg.600x600.jpg)
- 专利标题： Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors
-
申请号： US17183253申请日： 2021-02-23
-
公开(公告)号： US12030885B2公开(公告)日： 2024-07-09
- 发明人: Andrew W. Buesking , Richard B. Sparks , Andrew P. Combs , Brent Douty , Nikoo Falahatpisheh , Lixin Shao , Stacey Shepard , Eddy W. Yue , Artem Shvartsbart , David M. Burns , Daniel Levy
- 申请人： Incyte Corporation
- 申请人地址： US DE Wilmington
- 专利权人： Incyte Corporation
- 当前专利权人： Incyte Corporation
- 当前专利权人地址： US DE Wilmington
- 代理机构： Fish & Richardson P.C.
- 分案原申请号： US15631417 2017.06.23
- 主分类号： A61K31/53
- IPC分类号： A61K31/53 ; C07D471/04 ; C07D487/04 ; C07D519/00
![Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors](/abs-image/US/2024/07/09/US12030885B2/abs.jpg.150x150.jpg)
摘要：
This application relates to compounds of Formula (I):
or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
公开/授权文献
- US20220251087A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS 公开/授权日：2022-08-11
信息查询
